<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>RAPID: Curbing the COVID-19 outbreak in the United States</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>04/01/2020</AwardEffectiveDate>
<AwardExpirationDate>03/31/2021</AwardExpirationDate>
<AwardTotalIntnAmount>199993.00</AwardTotalIntnAmount>
<AwardAmount>199993</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>08010000</Code>
<Directorate>
<Abbreviation>BIO</Abbreviation>
<LongName>Direct For Biological Sciences</LongName>
</Directorate>
<Division>
<Abbreviation>DEB</Abbreviation>
<LongName>Division Of Environmental Biology</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Samuel Scheiner</SignBlockName>
<PO_EMAI>sscheine@nsf.gov</PO_EMAI>
<PO_PHON>7032927175</PO_PHON>
</ProgramOfficer>
<AbstractNarration>This project will produce a practical mathematical modeling framework that will assess pharmaceutical and non-pharmaceutical intervention strategies in the US, over the course of the COVID-19 pandemic. In the midst of this current unprecedented crisis, public health decisions must be made quickly when there is a large level of uncertainty about the burden of COVID-19 in the community. Research to evaluate intervention strategies can help decision-makers to identify the proper control measures and intensity needed for containment and mitigation of COVID-19. To accomplish these goals, the researchers will develop a mathematical framework that will provide estimates of healthcare demands and effectiveness of various containment and mitigation approaches at state and county levels in the U.S. An open-access, interactive dashboard will provide vital insights that policy makers can use to make and adjust informed decisions during the course of the pandemic depending on available resources as well as under various scenarios and locales.&lt;br/&gt;&lt;br/&gt;A stochastic modelling framework will be used. The framework will follow the natural history of the disease, with a compartmentalization of susceptible-exposed-infected-removed (SEIR) and stratified by 16 age groups. The model will be parametrized useing data representing contact patterns, demographic variables, hospitalizations, deaths, incidence, disease characteristics, and capacity of critical healthcare infrastructure (e.g., hospital beds) in US states and counties. To determine an optimal deployment strategy of diagnostic tests tailored to the stage of the COVID-19 outbreak, the researchers will simulate transmission dynamics of COVID-19 to project relevant outcomes of disease. Strategies will account for the available number of testing kits. As the symptoms of COVID-19 are difficult to distinguish from influenza, historical data trends will be used to adjust the number of cases of influenza-like-illness seeking medical treatment. The researchers will explore strategies ranging from testing of individuals presenting in hospitals with COVID-19 symptoms to age and risk dependent surveillance where individuals from high-risk areas would be tested. To assess the impact of various non-pharmaceutical interventions on COVID-19 transmission and the accompanying healthcare surge capacity, the researchers will explore the consequences of different public health measures such as contact tracing, self-quarantine, and self-isolation.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.</AbstractNarration>
<MinAmdLetterDate>03/30/2020</MinAmdLetterDate>
<MaxAmdLetterDate>02/01/2021</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.074</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>2027755</AwardID>
<Investigator>
<FirstName>Alison</FirstName>
<LastName>Galvani</LastName>
<PI_MID_INIT>P</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Alison P Galvani</PI_FULL_NAME>
<EmailAddress>Alison.Galvani@yale.edu</EmailAddress>
<PI_PHON>2037852642</PI_PHON>
<NSF_ID>000453347</NSF_ID>
<StartDate>03/30/2020</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>Abhishek</FirstName>
<LastName>Pandey</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Abhishek Pandey</PI_FULL_NAME>
<EmailAddress>abhishek.pandey@yale.edu</EmailAddress>
<PI_PHON>2037852642</PI_PHON>
<NSF_ID>000845777</NSF_ID>
<StartDate>02/01/2021</StartDate>
<EndDate/>
<RoleCode>Co-Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>Yale University</Name>
<CityName>New Haven</CityName>
<ZipCode>065208327</ZipCode>
<PhoneNumber>2037854689</PhoneNumber>
<StreetAddress>Office of Sponsored Projects</StreetAddress>
<StreetAddress2><![CDATA[P.O. Box 208327]]></StreetAddress2>
<CountryName>United States</CountryName>
<StateName>Connecticut</StateName>
<StateCode>CT</StateCode>
<CONGRESSDISTRICT>03</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>CT03</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>043207562</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>YALE UNIVERSITY</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM>043207562</ORG_PRNT_DUNS_NUM>
</Institution>
<Performance_Institution>
<Name><![CDATA[Yale University - School of Public Health]]></Name>
<CityName>New Haven</CityName>
<StateCode>CT</StateCode>
<ZipCode>065103210</ZipCode>
<StreetAddress><![CDATA[135 College Street, Suite 200]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>Connecticut</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>03</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>CT03</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>7242</Code>
<Text>Ecology of Infectious Diseases</Text>
</ProgramElement>
<ProgramReference>
<Code>096Z</Code>
<Text>COVID-19 Research</Text>
</ProgramReference>
<ProgramReference>
<Code>7914</Code>
<Text>RAPID</Text>
</ProgramReference>
<Appropriation>
<Code>0120</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2020~199993</FUND_OBLG>
<POR>
<DRECONTENT><![CDATA[<div class="porColContainerWBG"> <div class="porContentCol"><p><strong>NSF Outcomes<br /> <br /> </strong></p> <p>During the ongoing COVID-19 pandemic, the epidemic situation was continuously evolving. Supported by the NSF Grant, we conducted a series of data-driven research studies to evaluate control interventions necessary to contain the COVID-19 outbreak in the United States as well as to understand it&rsquo;s disease epidemiology.&nbsp; In the early phases of the COVID-19 outbreak in the United States, when there was growing concern over inadequacy of health resources, we developed a COVID-19 transmission model using demographics and contact patterns in the United States to project the potential hospital burden during the peak of the pandemic. We found that twice as many ICU beds would have been required than available during the pre-pandemic period at the peak of the first wave and encouraging self-isolation, policies such as paid sick leave had potential to delay the peak and give opportunity to expand hospital capacity.</p> <p>After inadequacies of testing capacity that plagued the initial phase of the outbreak in the US were addressed, it became critical to understand the underlying drivers of the COVID-19 transmission in the United States. We translated data from a clinical study to population level and evaluated the contribution of asymptomatic and pre-symptomatic individuals on overall transmission.&nbsp; We found that this silent transmission caused by asymptomatic and pre-symptomatic individuals is responsible for more than 50% of the overall attack rate and it can sustain an outbreak alone. Therefore, a symptom-based surveillance must be supplemented with a rapid contact-based surveillance to identify asymptomatic and pre-symptomatic individuals.</p> <p>We also evaluated COVID-19 mortality in Michigan by demographic and health characteristics, using individual-level linked death certificate and surveillance data collected by the Michigan Department of Health and Human Services from March 16 to October 26, 2020. Our findings demonstrated that Black populations are disproportionately burdened by COVID-19 mortality, even after accounting for demographic and underlying health.</p> <p>When deployment of the vaccine against COVID-19 commenced in December 2020, we simulated the vaccine deployment strategy of prioritizing healthcare workers and high-risk individuals adopted by the United States and assessed the impact of vaccination by varying vaccination coverage and vaccine efficacy. We found that if a vaccine with an efficacy of 90% is administered to 40% of the overall population of the United States, it can reduce the overall attack rate (percentage of individuals getting infected) to less than 2% from more than 7% across the same period without vaccination. The highest relative reduction would be observed among the elderly population. Moreover, vaccination would also reduce the adverse outcomes substantially. We also found that acceleration of vaccination was essential to avert the expected surge in COVID-19 hospitalizations, and deaths associated with widespread dissemination of variants of concern.</p> <p>Overall, supported by this grant, we conducted studies aimed at addressing the urgent needs arising during the pandemic by applying modeling, statistical and simulation tools to inform public health decisions pertaining to the optimal use of health resources and social intervention measures.</p> <p>&nbsp;</p><br> <p>            Last Modified: 08/04/2021<br>      Modified by: Alison&nbsp;P&nbsp;Galvani</p> </div> <div class="porSideCol"></div> </div>]]></DRECONTENT>
<POR_COPY_TXT><![CDATA[ NSF Outcomes      During the ongoing COVID-19 pandemic, the epidemic situation was continuously evolving. Supported by the NSF Grant, we conducted a series of data-driven research studies to evaluate control interventions necessary to contain the COVID-19 outbreak in the United States as well as to understand itâ€™s disease epidemiology.  In the early phases of the COVID-19 outbreak in the United States, when there was growing concern over inadequacy of health resources, we developed a COVID-19 transmission model using demographics and contact patterns in the United States to project the potential hospital burden during the peak of the pandemic. We found that twice as many ICU beds would have been required than available during the pre-pandemic period at the peak of the first wave and encouraging self-isolation, policies such as paid sick leave had potential to delay the peak and give opportunity to expand hospital capacity.  After inadequacies of testing capacity that plagued the initial phase of the outbreak in the US were addressed, it became critical to understand the underlying drivers of the COVID-19 transmission in the United States. We translated data from a clinical study to population level and evaluated the contribution of asymptomatic and pre-symptomatic individuals on overall transmission.  We found that this silent transmission caused by asymptomatic and pre-symptomatic individuals is responsible for more than 50% of the overall attack rate and it can sustain an outbreak alone. Therefore, a symptom-based surveillance must be supplemented with a rapid contact-based surveillance to identify asymptomatic and pre-symptomatic individuals.  We also evaluated COVID-19 mortality in Michigan by demographic and health characteristics, using individual-level linked death certificate and surveillance data collected by the Michigan Department of Health and Human Services from March 16 to October 26, 2020. Our findings demonstrated that Black populations are disproportionately burdened by COVID-19 mortality, even after accounting for demographic and underlying health.  When deployment of the vaccine against COVID-19 commenced in December 2020, we simulated the vaccine deployment strategy of prioritizing healthcare workers and high-risk individuals adopted by the United States and assessed the impact of vaccination by varying vaccination coverage and vaccine efficacy. We found that if a vaccine with an efficacy of 90% is administered to 40% of the overall population of the United States, it can reduce the overall attack rate (percentage of individuals getting infected) to less than 2% from more than 7% across the same period without vaccination. The highest relative reduction would be observed among the elderly population. Moreover, vaccination would also reduce the adverse outcomes substantially. We also found that acceleration of vaccination was essential to avert the expected surge in COVID-19 hospitalizations, and deaths associated with widespread dissemination of variants of concern.  Overall, supported by this grant, we conducted studies aimed at addressing the urgent needs arising during the pandemic by applying modeling, statistical and simulation tools to inform public health decisions pertaining to the optimal use of health resources and social intervention measures.          Last Modified: 08/04/2021       Submitted by: Alison P Galvani]]></POR_COPY_TXT>
</POR>
</Award>
</rootTag>
